Tiotropium mist (Respimat) increases mortality risk, authors say
www.pulmccm.org
Singh et al analyzed 5 randomized trials comparing tiotropium mist to placebo, and found a 46% relative increased risk of all-cause mortality among the treated arms. The Respimat inhaler is available in Europe, but the FDA has not approved it in the US.
Tiotropium mist (Respimat) increases mortality risk, authors say
Tiotropium mist (Respimat) increases…
Tiotropium mist (Respimat) increases mortality risk, authors say
Singh et al analyzed 5 randomized trials comparing tiotropium mist to placebo, and found a 46% relative increased risk of all-cause mortality among the treated arms. The Respimat inhaler is available in Europe, but the FDA has not approved it in the US.